Lv11
50 积分 2021-02-20 加入
Benefit with glofitamab plus chemotherapy in transplant-ineligible R/R DLBCL
3小时前
待确认
Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma
5天前
已完结
Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia
11天前
已完结
Bruton Tyrosine Kinase Inhibition: an Effective Strategy to Manage Waldenström Macroglobulinemia
10个月前
已完结
Blinatumomab Therapy for Low Level Minimal Residual Disease Detected By Next-Generation Sequencing in Adult B-Cell Acute Lymphoblastic Leukemia
11个月前
已完结
International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma
11个月前
已完结
Cardiovascular side effects of signaling pathway inhibitors in chronic lymphocytic leukemia therapy
11个月前
已关闭
Overcoming Resistance in Chronic Lymphocytic Leukemia—Maybe Less Is More?
11个月前
已完结
Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein–Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial
11个月前
已完结
Current approach to Waldenström macroglobulinemia
1年前
已完结
皖公网安备34019202002308
